chufangao/CTO huggingface dataset:
Clinical trial NCT04971512: A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.
Official title: A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP-721 in Healthy Subjects (Part 1) and the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of EDP-721 in Combination With EDP-514 in Patients With Chronic Hepatitis B Virus Infection (Part 2)
Sponsor: Enanta Pharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to adverse safety signals in Part 1 (HV)
Enrollment: 26.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-08-02
Primary completion date: 2021-12-20
Completion date: 2021-12-20
Clinical trial NCT03623984: Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
Official title: Molecular-Guided Surgery for Pancreatic and Gastrointestinal Neuroendocrine Cancers
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: no partipants
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-07
Primary completion date: 2022-06-07
Completion date: 2023-06-07
Clinical trial NCT03097328: Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Official title: A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-01
Primary completion date: 2021-07-20
Completion date: 2024-04-24
Baseline population: Baseline data was assessed in 38 eligible and treated patients. 1 patient who was deemed as ineligible and did not receive treatment was excluded from baseline analysis.
Plan to share individual participant data: NO
Clinical trial NCT04626947: Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
Official title: Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-10-30
Primary completion date: 2024-04-24
Completion date: 2024-05-31
Plan to share individual participant data: NO
Clinical trial NCT05238896: BARIcitinib Cognitive Emotional and Neural signaTuRE
Official title: BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE)
Acronym: BARICENTRE
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Difficulties of inclusion in the study following expiry of the experimental treatment. The time required to supply the study treatment is too long to obtain conclusive results at the end of the study.
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-27
Primary completion date: 2023-02-23
Completion date: 2023-03-31
Plan to share individual participant data: YES
IPD sharing description: Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients.~Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
IPD time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
IPD access criteria: Researchers who provide a methodological sound proposal.
Clinical trial NCT04875975: A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Sponsor: UCB Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues.
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-27
Primary completion date: 2024-03-08
Completion date: 2024-04-26
Plan to share individual participant data: YES
IPD sharing description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Clinical trial NCT04053543: CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
Official title: A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects With Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301
Sponsor: Complexa, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: LOE
Enrollment: 33.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-09
Primary completion date: 2020-08-12
Completion date: 2020-08-12
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02336906: Urotherapy vs. Urotherapy With Constipation Treatment for Children With Lower Urinary Tract Dysfunction
Official title: A Controlled Randomized, Physician Blinded Study to Assess Isolated Uro-therapy vs. Urotherapy With Constipation Treatment for Patients With Lower Urinary Tract Dysfunction (LUTD) Not Meeting ROME-III Constipation Criteria
Sponsor: Rabin Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Changes in departmental staff have led to a cut in research alotments.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-31
Primary completion date: 2020-07-31
Completion date: 2020-12-31
Clinical trial NCT02141282: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Official title: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 127.0 (ACTUAL)
Number of arms: 4.0
Start date: 2014-09-10
Primary completion date: 2021-12-22
Completion date: 2021-12-22
Baseline population: All treated participants
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT03645408: The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers
Official title: The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers
Sponsor: Boston Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to COVID-19 hospital-wide policies halting recruitment
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-02
Primary completion date: 2021-07-01
Completion date: 2021-07-01
Limitations and caveats: The small sample size reflects the early termination of the research which was halted due to Covid 19 precautions.
Plan to share individual participant data: NO
Clinical trial NCT03104335: Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
Official title: Apatinib for Advanced Soft Tissue Sarcoma Patients After Failure of Traditional Therapy: an One-armed, Phase 2, Open-label, Multicenter Prospective Trial
Sponsor: Peking University People's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Not enough patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-01
Primary completion date: 2019-06-30
Completion date: 2020-03-01
Plan to share individual participant data: NO
Clinical trial NCT03969641: Safety of RIV4 Versus IIV4 in Pregnant Women
Official title: A Prospective, Randomized, Clinical Trial to Compare Adverse Birth Outcomes in Pregnant Women Receiving Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4)
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 384.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-05
Primary completion date: 2021-09-29
Completion date: 2021-09-29
Baseline population: Participants who received study product.
Plan to share individual participant data: NO
Clinical trial NCT02495077: Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Official title: Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 290.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-11-02
Primary completion date: 2021-07-23
Completion date: 2021-07-23
Baseline population: Intent-to-treat population included all transplanted and randomized participants who received the infliximab/placebo infusion
Clinical trial NCT04346628: Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19
Official title: A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 149.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-12
Primary completion date: 2021-04-16
Completion date: 2021-04-16
Baseline population: Baseline characteristics were assessed for the symptomatic modified ITT (smITT) Analysis Set (participants who reported at least one symptom other than mild cough, mild fatigue, or decreased taste/smell at baseline), and for the modified ITT (mITT) Analysis Set (participants who were symptomatic with positive RT-PCR result at baseline).
Plan to share individual participant data: NO
IPD sharing description: No current plan to share individual participant data (IPD).
Clinical trial NCT03865407: Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease
Official title: Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease
Sponsor: Virginia Commonwealth University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: inability to achieve recruitment goals at a single center and given the current pandemic conditions
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-10
Primary completion date: 2020-10-07
Completion date: 2020-10-07
Plan to share individual participant data: NO
Clinical trial NCT03161678: CES1 Crossover Trial of Clopidogrel and Ticagrelor
Official title: Impact of Genetic Variation in CES1 on Antiplatelet Therapy
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 111.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-08-22
Primary completion date: 2022-12-12
Completion date: 2022-12-12
Plan to share individual participant data: YES
IPD sharing description: It is possible that deidentified data will be deposited into large public databases as per NIH data sharing policies (e.g. database of Genotypes and Phenotypes \[dbGAP\], Pharmacogenomics Knowledgebase \[PharmGKB\]). Data to be shared would include, but not limited to, anthropometric data, study outcome data, and relevant covariate data used in statistical models of association. It is anticipated that data would be available after the completion of the trial. The data will be obtained from the participants and the study-related research procedures.
Clinical trial NCT01390948: A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
Official title: A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, or Peduncular High-Grade Glioma
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 124.0 (ACTUAL)
Number of arms: 3.0
Start date: 2011-10-18
Primary completion date: 2016-02-05
Completion date: 2020-01-29
Clinical trial NCT05392127: A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers
Official title: A Single-center, Open-label, Single-arm, Fixed-sequence Study to Evaluate the Pharmacokinetic Effects of SHR0302 Tablets on Substrates of CYP3A4, CYP2C8, CYP2C9, CYP2C19 in Healthy Volunteers
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-07-15
Primary completion date: 2022-08-18
Completion date: 2022-08-18
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03066817: Vitamin D and Bone Homeostasis in Ortho Polytrauma Patients
Official title: A Pilot Study of Role of Vitamin D in Regulation of Bone Homeostasis in Orthopaedic Polytrauma Patients
Sponsor: New York City Health and Hospitals Corporation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: Waiting for annual IRB progress report to be reviewed and approved
Enrollment: 60.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2017-07-01
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: NO
IPD sharing description: Individual participant data are not planned to be shared.
Clinical trial NCT02146547: European Long-acting Antipsychotics in Schizophrenia Trial
Official title: European Long-acting Antipsychotics in Schizophrenia Trial
Acronym: EULAST
Sponsor: UMC Utrecht (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 536.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-02-28
Primary completion date: 2020-08-26
Completion date: 2020-08-26
Plan to share individual participant data: NO
Clinical trial NCT03238638: A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
Official title: A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: PI did not attempt to open the study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-30
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT03987620: Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (AVVC).
Acronym: Vanish 306
Sponsor: Scynexis, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 455.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-07
Primary completion date: 2020-03-29
Completion date: 2020-04-29
Clinical trial NCT05160558: A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
Official title: A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's Decision
Enrollment: 8.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-02-02
Primary completion date: 2023-07-25
Completion date: 2023-07-25
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Clinical trial NCT03492463: The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products
Official title: The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products
Acronym: ENDS-Switch
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 94.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-08-06
Primary completion date: 2021-05-31
Completion date: 2021-05-31
Plan to share individual participant data: NO
Clinical trial NCT03940651: Cardiac and Renal Biomarkers in Arthroplasty Surgery
Official title: Effect of Spinal Versus General Anesthesia on Cardiac and Renal Biomarker Levels in Hip and Knee Arthroplasty Surgery
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Funding ended
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-04
Primary completion date: 2020-09-23
Completion date: 2020-09-23
Plan to share individual participant data: NO
Clinical trial NCT04224740: Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer
Official title: A Phase II Trial of Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer
Acronym: HERCULES
Sponsor: Latin American Cooperative Oncology Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-15
Primary completion date: 2023-11-13
Completion date: 2023-11-13
Plan to share individual participant data: NO
Clinical trial NCT02584634: Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
Official title: A PHASE 1B/2, OPEN-LABEL, DOSE-FINDING STUDY TO EVALUATE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH EITHER CRIZOTINIB OR PF-06463922 IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522)
Enrollment: 43.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-18
Primary completion date: 2021-02-02
Completion date: 2022-07-13
Baseline population: The baseline analysis population included all participants who received at least one dose of study drug. Participants were classified according to the study treatment actually received. If a participant received more than one treatment the participant was classified according to the first treatment received.
Limitations and caveats: Enrollment in the study was terminated early based on the changing landscape in treatment options for treatment naïve ALK positive NSCLC. This decision was not due to any safety concerns or regulatory interactions. All participants on active treatment at the time of the early enrollment termination could continue treatment and follow up per the protocol.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT01300611: TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
Official title: Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation
Acronym: USBTXA127CBT
Sponsor: Tarix Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Enrollment: 20.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2011-01-31
Primary completion date: 2020-12-31
Completion date: 2020-12-31